Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erick Gamelin

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Journal of Cancer Research and Clinical Oncology|October 1, 2011
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancerClaus-Henning Köhne, Ralf Hofheinz, Laurent Mineur, et al.
BMC Cancer|October 2, 2012
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II studyJosef Thaler, Meinolf Karthaus, Laurent Mineur, et al.
Clinical Pharmacokinetics|October 10, 2007
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration scheduleMarie-Christine Etienne-Grimaldi, Eric François, Jean-Michel Cardot, et al.
Cancer Investigation|March 20, 2003
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen)Christophe Louvet, Fabien Carrat, Frédéric Mal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancerErick Gamelin, Remy Delva, Jacques Jacob, et al.
The Journal of Biological Chemistry|February 5, 2011
Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteinsSophie de Carné Trécesson, Yannis Guillemin, Audrey Bélanger, et al.
The Oncologist|April 12, 2005
Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancerCatherine Abrial, Isabelle Van Praagh, Rémi Delva, et al.
Cancer Chemotherapy and Pharmacology|June 3, 2015
Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapiesBenjamin Wu, Rebeca Melara, Erik Rasmussen, et al.
Mabs|June 12, 2013
Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodiesChristophe Passot, Nicolas Azzopardi, Sylvaine Renault, et al.
Pharmacogenomics|December 1, 2015
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximabJérôme Rollin, Audrey Payancé, Valérie Gouilleux-Gruart, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Journal of Cancer Research and Clinical Oncology|October 1, 2011
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancerClaus-Henning Köhne, Ralf Hofheinz, Laurent Mineur, et al.
BMC Cancer|October 2, 2012
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II studyJosef Thaler, Meinolf Karthaus, Laurent Mineur, et al.
Clinical Pharmacokinetics|October 10, 2007
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration scheduleMarie-Christine Etienne-Grimaldi, Eric François, Jean-Michel Cardot, et al.
Cancer Investigation|March 20, 2003
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen)Christophe Louvet, Fabien Carrat, Frédéric Mal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancerErick Gamelin, Remy Delva, Jacques Jacob, et al.
The Journal of Biological Chemistry|February 5, 2011
Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteinsSophie de Carné Trécesson, Yannis Guillemin, Audrey Bélanger, et al.
The Oncologist|April 12, 2005
Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancerCatherine Abrial, Isabelle Van Praagh, Rémi Delva, et al.
Cancer Chemotherapy and Pharmacology|June 3, 2015
Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapiesBenjamin Wu, Rebeca Melara, Erik Rasmussen, et al.
Mabs|June 12, 2013
Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodiesChristophe Passot, Nicolas Azzopardi, Sylvaine Renault, et al.
Pharmacogenomics|December 1, 2015
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximabJérôme Rollin, Audrey Payancé, Valérie Gouilleux-Gruart, et al.
Pageof 5